Congenital heart disease (CHD) is the most frequently occurring congenital disorder in newborns and is the most frequent cause of infant death from birth defects. The aetiology of CHD is largely unknown. Epidemiological studies reveal a significant environmental contribution to the pathogenesis of CHD[@b1][@b2]. Familial aggregation and twin studies indicate the presence of genetic factors for susceptibility to this condition[@b3][@b4][@b5]. Except for a few types of CHD induced by a single gene mutation, the majority of CHDs are polygenic diseases affected by both genetic and environmental factors.

The importance of genetic factors in the development of CHD is also supported by recent data from genome-wide association studies (GWASs). Data from these studies have confirmed that a region on chromosome 4p16 adjacent to the *MSX1* and *STX18* genes was associated with the risk of ostium secundum atrial septal defect (ASD)[@b6], and rs2228638 in *NRP1* on 10p11 significantly increased the risk of Tetralogy of Fallot (TOF)[@b7]. In our studies, we identified *HOMEZ and PLAGL1* as pathogenic genes in Chinese patients with isolated ventricular septal defects (VSDs)[@b8][@b9]. In addition, our proteomic study revealed plasma protein changes in CHD patients[@b10].

The 5,10-methylenetetrahydrofolate reductase (*MTHFR*) gene is located on chromosome 1 at 1p36.3. MTHFR is the key metabolic enzyme of homocysteine (Hcy). It catalyses 5,10-methylenetetrahydrofolate reduction to 5-methyltetrahydrofolate, which as a methyl donor induces Hcy remethylation to methionine[@b11]. A common C677T mutation (rs1801133) in the *MTHFR* gene has been described, which results in the conversion of the amino acid alanine to valine at position 226 in the protein. This mutation was associated with a 50% reduction of MTHFR enzyme activity, an increase in plasma Hcy concentration and a decrease in plasma folic acid concentration. Another polymorphism (A1298C, rs1801131) is located in exon 7, within the presumptive regulatory domain, and results in a glutamate-to-alanine change with decreased enzyme activity in vitro[@b12]. It has been reported that *MTHFR* polymorphisms play important roles in diseases. For example, neural tube defects and pregnancy complications appear to be linked to impaired MTHFR function[@b13][@b14].

Since Wenstrom first noted an association between *MTHFR* gene polymorphism and susceptibility to CHD[@b15], other studies have been undertaken to replicate this work. However, previous case-control reports have yielded inconsistent results. Wang and co-workers carried out a meta-analysis involving 2,554 CHD patients and 3,838 controls by searching the electronic literature for articles published before *July 22, 2012.* They suggested that the infant and maternal *MTHFR* C667T polymorphism may be associated with an increased occurrence of CHD[@b16]. By contrast, Mamasoula and co-workers indicated that the *MTHFR* C677T polymorphism, which directly influences plasma folate levels, is not associated with the risk of CHD[@b17]. Therefore, we performed an up-dated meta-analysis of all published studies (until *Jun, 2014*) to investigate the association between *MTHFR* polymorphisms (C677T and A1298C) and the risk of CHD.

Methods
=======

Search strategy
---------------

We conducted a comprehensive search of Embase, Ovid, Web of Science, the Cochrane database, Medline (PubMed), the Chinese Biomedical Literature Database (CBM-disc, 1979--2014), the database of National Knowledge Infrastructure (CNKI, 1979--2014) and the full paper database of Chinese Science and Technology of Chongqing (VIP, 1989--2014) to identify suitable studies published before *Jun, 2014.* The following keywords were used for searching: ("congenital heart" OR "congenital cardiac" OR "heart defect\*" OR "congenital car\*") AND ("polymorphism\*" OR "variant\*") AND ("methylenetetrahydrofolate reductase" OR "MTHFR"). The most complete and recent results were used when there were multiple publications from the same study group. The references of reviews and retrieved articles were also searched simultaneously to find additional eligible studies.

Inclusion criteria
------------------

Two investigators reviewed all identified studies independently to determine whether an individual study was eligible for inclusion. The selection criteria for studies to be considered for this meta-analysis were as follows: 1) *MTHFR* polymorphisms in CHD; 2) case-control or case-cohort study; 3) proper CHD diagnosis criteria; 4) original data; 5) human subjects, not animal studies. We expected the clinical assessment of the patients to include anthropometric measurement and physical examination for dysmorphism and malformation, and diagnostic studies to include chest X-ray examination, electrocardiogram, ultrasonic echocardiogram, etc. Studies would be excluded if the necessary information could not be obtained.

Data extraction
---------------

Two investigators extracted the data independently, and a third investigator reviewed the result. The following information was extracted from each study: first author, year of publication, study population (country, ethnicity), the number of patients and controls in the study, genotype information, genotype methods, and main types of CHD. If any data essential to the analysis were not available from a study, best efforts were made to contact the authors to fill in the missing data.

Statistical analysis
--------------------

Allele frequencies for the *MTHFR* (C677T and A1298C) polymorphisms from each study were determined by the allele counting method[@b18]. The genotype distributions of controls were used to estimate the frequency of the putative risk allele (-677T and -1298C) using the inverse variance method[@b19][@b20]. The Hardy-Weinberg Equilibrium (*HWE*) is the most fundamental rule of population genetics. It prescribes the genotype frequencies at a locus in terms of its allele frequencies in a population. In the most general form, it states that selection, migration, and random genetic drift occur with random mating in a population in the absence of mutation[@b21]. The deviation from *HWE* for the distribution of the allele frequencies was analysed by Fisher\'s exact test in control groups. We examined the contrast of a vs. A, aa vs. AA, aa vs. Aa and also examined the recessive genetic model (aa vs. AA+Aa) and the dominant genetic model (Aa+aa vs. AA). The associations between *MTHFR* polymorphisms and CHD susceptibility were estimated by OR and its 95% CI. The significance of the pooled OR was determined by the Z-test; *P* \< 0.05 was considered statistically significant. To evaluate the specific effects of ethnicity, stratified analyses were performed.

Heterogeneity across the eligible studies was tested using the Q-test, and the results were considered statistically significant when *P* \< 0.1[@b22][@b23]. Heterogeneity was also quantified with the *I*^*2*^ metric (*I*^*2*^*= (Q - df)/Q × 100%*; *I*^*2*^ \< 25%, no heterogeneity; *I*^*2*^ = 25--50%, moderate heterogeneity; *I*^*2*^ = 50--75%, large heterogeneity; *I*^*2*^ \> 75%, extreme heterogeneity). When the effects were assumed to be homogenous (*P* \> 0.1, *I*^*2*^ \< 50%), the fixed-effects model was used; otherwise, the random-effects model was more appropriate[@b24][@b25][@b26]. Sensitivity analysis was performed to evaluate the stability of the results. If more than seven studies were included, Begg\'s test was used to measure publication bias, which was shown as a funnel plot[@b27][@b28]. *P* \< 0.05 was considered representative of statistically significant publication bias. All analyses were performed using STATA software, version 10.0 (Stata Corporation, College Station, TX, USA), Review Manager (RevMan version 5.1.1, The Nordic Cochrane Centre: <http://ims.cochrane.org/revman/download>) and R statistical software (version 2.15.2, <http://www.r-project.org>).

Results
=======

Studies included in the meta-analysis
-------------------------------------

A total of 126 abstracts that met the inclusion criteria were retrieved through the databases. Two reviewers then selected the relevant studies independently. Forty-five relevant studies that described the association between the *MTHFR* polymorphism and CHD were identified. However, after reading the full articles and contacting the authors, we excluded five meta-analysis studies[@b29][@b30][@b31][@b32][@b33], four family-based studies[@b34][@b35][@b36][@b37], and one study in which information could not be obtained even after the authors were contacted[@b38]. [Figure 1](#f1){ref-type="fig"} shows the process of study selection and exclusion, with specification of reasons. Finally, 35 studies that met the inclusion criteria, corresponding to 9,329 CHD children and 15,076 normal controls, 3,232 mothers with CHD offspring and 27,174 normal controls for the C677T polymorphism and 1,761 CHD children and 1,868 normal controls/705 mothers with CHD offspring and 15,458 controls for the A1298C polymorphism, were considered in the meta-analysis[@b15][@b17][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58][@b59][@b60][@b61][@b62][@b63][@b64][@b65][@b66][@b67][@b68][@b69][@b70][@b71]. The main characteristics of the included studies are listed in [Table 1](#t1){ref-type="table"}--[2](#t2){ref-type="table"}.

Pooled Prevalence of *MTHFR* -677T and -1298C in the Controls
-------------------------------------------------------------

The pooled *MTHFR* --677T allele frequency determined using the random-effects model was 28.99% (95 CI: 26.14%--32.02%) in the Caucasian paediatric population and was 42.28% (95% CI: 34.17%--50.83%) in the Asian paediatric population. There was no heterogeneity among the Caucasian and Asian maternal population studies. The *MTHFR* --677T allele frequency was 31.76% (95 CI: 30.14%--33.43%) in the Caucasian maternal population and was 41.51% (95% CI: 37.50%--45.64%) in the Asian maternal population.

The pooled --1298C allele frequency in the fixed-effects model was 33.12% (95 CI: 29.80%--36.61%) in the Caucasian paediatric population and was 31.09% (95% CI: 25.34%--37.46%) in the Caucasian maternal population using the random-effects model.

Association between *MTHFR* C677T polymorphism and risk of CHD
--------------------------------------------------------------

We investigated the association between the *MTHFR* C677T polymorphism and the risk of CHD for each study. When all the eligible studies were pooled in the overall population of children with random-effects models, significant associations were observed in all genetic models: T versus C (OR = 1.248, 95% CI: 1.093--1.426; *P* = 0.001), TT versus CC (OR = 1.485, 95% CI: 1.140--1.935; *P* = 0.003), and TT versus CT (OR = 1.312, 95% CI: 1.100--1.565; *P* = 0.003), the dominant model (OR = 1.240, 95% CI: 1.053--1.461; *P* = 0.010), and the recessive model (OR = 1.410, 95% CI: 1.139--1.724; *P* = 0.001;([Figure 2](#f2){ref-type="fig"}). In addition, significant associations were observed in the overall maternal population in all genetic models for T versus C (OR = 1.215, 95% CI: 1.085--1.361; *P* = 0.001), TT versus CC (OR = 1.488, 95% CI: 1.169--1.859; *P* = 0.001), TT versus CT (OR = 1.315, 95% CI: 1.042--1.659; *P* = 0.021), the dominant model (OR = 1.258, 95% CI: 1.144--1.383; *P* = 2.14e-6), and the recessive model (OR = 1.408, 95% CI: 1.128--1.757; *P* = 0.002; ([Figure 3](#f3){ref-type="fig"}). The Z-test indicated that the pooled ORs were statistically significant.

In the stratified analysis by ethnicity, significant associations were found when all studies were pooled with fixed or random-effects models for T versus C (OR = 1.163, 95% CI: 1.008--1.342; *P* = 0.039) in Caucasian children, and for T versus C (OR = 1.125, 95% CI: 1.043--1.214; *P* = 0.002), dominant model (OR = 1.216, 95% CI: 1.096--1.348; *P* = 2.24e-4) in the Caucasian maternal population. In addition, significant associations were found when all studies were pooled in fixed or random-effects models for all genetic models in Asian children and the maternal population. The main results of meta-analysis are shown in [Table 3](#t3){ref-type="table"}.

Association between MTHFR A1298C polymorphism and risk of CHD
-------------------------------------------------------------

We investigated the association between the *MTHFR* A1298C polymorphism and the risk of CHD for each study. Overall, when all the eligible studies were pooled in the fixed-effects model, significant associations were observed for CC vs. AC (OR = 1.354, 95% CI: 1.022--1.793; *P* = 0.034), and for the recessive model (OR = 1.322, 95% CI: 1.015--1.732; *P* = 0.038) in the overall paediatric population. The main results of the meta-analysis are shown in [Table 4](#t4){ref-type="table"}.

In the analysis stratified by ethnicity, significant associations were found in the Caucasian paediatric population when all studies were pooled in the fixed-effects model for CC versus AC (OR = 1.484, 95% CI: 1.035--2.128; *P* = 0.032; [Figure 4](#f4){ref-type="fig"}). The main results of the meta-analysis are shown in [Table 4](#t4){ref-type="table"}.

Sensitivity analyses
--------------------

We removed the studies due to the genotype distribution in the control groups deviating from *HWE*. We found that the corresponding ORs for the C677T polymorphism for the TT vs. CT and recessive models in the overall paediatric population and for all genetic types in the overall maternal population and the Asian maternal population were not substantially altered ([Table 5](#t5){ref-type="table"}). This finding supports the reliability of the results.

Publication bias
----------------

Begg\'s test and a funnel plot were performed to assess the publication bias of the literature. We detected publication biases for the C677T polymorphism for the T vs. C and dominant models in the Caucasian paediatric population ([Table 3](#t3){ref-type="table"}). This might represent a limitation of our analysis because the studies with null findings, especially those with small sample size, were less likely to be published. By using the trim and fill method, we showed that, if the publication bias was the only source of the funnel plot asymmetry, they needed two and one more studies, respectively, to balance the funnel plot. The adjusted risk estimate was attenuated. The adjusted OR for T vs. C was 1.142 (95% CI: 0.729--1.786) and for the dominant model was 1.253 (95%CI: 0.738--2.133). The results suggest no evidence of publication biases in other genetic models and populations ([Figure 5](#f5){ref-type="fig"}).

Discussion
==========

It is estimated that 7.9 million children are born with a serious birth defect of genetic or partially genetic origin each year in the world. CHDs are the most commonly occurring conditions. However, the aetiology of CHDs is largely unknown, and there are no established strategies for reducing their public health impact.

Many studies have demonstrated that genetic factors play important roles in the pathogenesis of CHD. In our previous studies, we have detected several novel variations of the *PLAGL1* and *HOMEZ* genes in Chinese patients with isolated VSD. We believe that these two genes are directly linked aetiologically with isolated VSD in the population[@b8][@b9]. In addition, the results of recent genome-wide association studies indicated that a region on chromosome 4p16 adjacent to the *MSX1* and *STX18* genes was associated (*P* = 9.5 × 10^−7^) with the risk of ostium secundum ASD[@b6]. These studies also showed that 1p12 (rs2474937 near *TBX15*; *P* = 8.44 × 10^−10^) and 4q31.1 (rs1531070 in *MAML3*; P = 4.99 × 10^−12^) were associated with congenital heart malformations in Han Chinese populations[@b72].

In 1999, Kapusta and associates first reported that maternal hyperhomocysteinaemia is correlated with an increased risk of CHDs[@b73]. More recently, Hobbs and co-workers studied mothers whose pregnancies were affected by congenital heart defects (224 case subjects) or unaffected by any birth defect (90 control subjects) and identified Hcy, S-adenosylhomocysteine, and methionine as the most important biomarkers predictive of case or control status[@b36]. The MTHFR protein is a key enzyme in Hcy metabolism. The *MTHFR* gene is located on chromosome 1 at 1p36.3. The major product of the *MTHFR* gene is a catalytically active 77 kDa protein that catalyses the conversion of 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, the major circulating form of folate. Two common genetic polymorphisms associated with reduced MTHFR activity have been identified. The C677T polymorphism is located in exon 4 at the folate-binding site and results in an alanine-to-valine substitution. In healthy homozygous subjects, the 677TT genotype is associated with higher total Hcy and lower folate plasma level. The other polymorphism (A1298C) is in exon 7 within the presumptive regulatory domain and results in a glutamate-to-alanine change. Heterozygosity and homozygosity are associated neither with higher total Hcy nor lower folate plasma concentration. The *MTHFR* gene polymorphisms are directly linked with many diseases[@b20][@b74]. Our recent meta-analysis demonstrated that the *MTHFR* C677T polymorphism is associated with the risk of myocardial infarction in young/middle-aged Caucasians and is associated with susceptibility to preeclampsia[@b20][@b74].

A number of studies have investigated the association between *MTHFR* genotype and the risk of CHD. In fact, in the last few years, several case--control studies were performed on this topic. However, the results are inconclusive. The two most recent meta-analyses for associations between polymorphism and CHD also led to conflicting conclusions. By reviewing all studies published before *April, 2011,* Yin and co-workers suggested that the foetal and paternal *MTHFR* C667T gene may be associated with an increased occurrence of CHD[@b32]. By contrast, after analysis of 7,698 cases and 13,159 controls by reviewing studies published before *2010*, Mamasoula and co-workers indicated that the same polymorphism, which directly influences plasma folate levels, is not associated with CHD risk[@b17]. Others also conducted meta-analysis to evaluate the association between MTHFR polymorphism and CHD[@b29][@b30][@b31]. It is possible that the relatively small sample size of these studies affected the accuracy of the results. Therefore, it is essential to re-perform a meta-analysis to evaluate the association. In our present study, we enlarged the sample size to 24,405 participants (9,329 CHD children and 15,076 normal controls), and performed sensitivity analysis to evaluate the stability of the results. In addition, we are the first to evaluate the association between the *MTHFR* A1298C polymorphism and CHD by meta-analysis. We are indebted to Dr. Christensen from McGill University for kindly allowing us access to his previously un-published data for this meta-analysis.

Our results indicate that the frequency of the putative risk allele -677T was 28.99% in Caucasian children and 31.76% in the Caucasian maternal population, whereas the frequency of -677T was 42.28% in Asian paediatric and 41.51% in the Asian maternal population. In addition, the pooled --1298C allele frequency was 33.12% in Caucasian children and 31.09% in the Caucasian maternal population. The meta-analysis results showed that associations exist between the *MTHFR* C677T polymorphism and susceptibility to CHD for all genetic models in all paediatric and maternal populations, especially in the Asian population. We also detected a significant association in the genetic model for T vs. C in the Caucasian paediatric population and in T vs. C and TT vs. CT for the Caucasian maternal population ([Table 3](#t3){ref-type="table"}). In our analysis of the A1298C polymorphism, we detected an association in the genetic model for TT vs. CT in the Caucasian paediatric population ([Table 4](#t4){ref-type="table"}). The results showing significant association for all genetic models in the overall maternal population and the Asian maternal population, and for the TT vs. CT and recessive models in the overall paediatric population were found to be stable and reliable by sensitivity analyses ([Table 5](#t5){ref-type="table"}).

Some limitations of this meta-analysis should be discussed. First, significant heterogeneity was observed in some genetic models when we pooled ORs. Under this condition, we used the random-effects model to pool the data. Sensitivity analysis was performed to evaluate the stability of the crude results. Second, publication biases appear to substantially contaminate the literature with regard to some genetic associations. The results of the trim and fill method demonstrated that the publication biases may affect the stability of positive results.

In conclusion, our results support the *MTHFR* --677T allele as a susceptibility factor for CHD in the Asian maternal population and the -1298C allele as a risk factor in the Caucasian paediatric population. Because of the heterogeneity and publication bias, we believe that other positive results may not be stable in our meta-analysis. A large number of homogeneous studies should be performed to evaluate these crude results in the future.
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###### The detailed characteristics of all eligible studies for *MTHFR* C677T polymorphism

                                                                                     *MTHFR* C677T                                                                                                           
  ---------------------------------------------------- ------ ----------------- ------------------- ------ ----- ------ ------ ------ ------- ----- ----- ----- ------ ------ ------ ------- --------------- ---------------------------------------------------------------------------------------------
  Junker et al                                          2001     Germany (C)            52            42    21    129     78     21    0.087   ---   ---   ---   ---    ---    ---     ---      PCR-RFLP         PS, HLHS, CoA, AVS, d-TGA, ASD, VSD, AVSD, TOF, PDA, DIV, PA, TA, Ebstein\'s Anomaly.
  Wenstrom et al                                        2001     USA(90% C)             17            8      1    104     9      3     0.006   ---   ---   ---   ---    ---    ---     ---      PCR-RFLP      HLV, HRV, CoA, PS, PA, TA, LVA, Atrioventricular Canal, Truncus Arteriosus, DORA, ASD, VSD.
  Liu et al                                             2002      China (A)             ---          ---    ---   ---    ---    ---     ---     5    14     8     2      15     3     0.068     PCR-RFLP                              VSD ASD, TOF, PDA, Single Atrium/Ventricle
  Storti et al                                          2003      Italy (C)             28            55    20     52    108     40    0.259   27    53    23     52    108     40    0.259     PCR-RFLP                                     VSD,TOF, DORV, PA, d-TGA, AC
  Nurk et al                                            2004     Norway (C)             ---          ---    ---   ---    ---    ---     ---    12    12     1    7165   6037   1282   0.842      RT-PCR                                       Congenital Anomalies Heart
  Li et al                                              2005      China (A)             32            94    61     20     57     25    0.320   32    90    61     20     57     25    0.320     PCR-RFLP                                          VSD, ASD, PDA, TOF,
  LEE et al                                             2005      China (A)             110           89    14    114     68     13    0.556   ---   ---   ---   ---    ---    ---     ---      PCR-DHPLC          AP Window, ASD, CoA, PS, DILV, DORV, ECD, IAA, LAI, PA, PDA, RAI, TGA, TOF, VSD.
  Shaw et al                                            2005       USA (C)              69            68    16    180    202     52    0.753   ---   ---   ---   ---    ---    ---     ---        ARRAY                        TOF, d-TGA, Truncus Arteriosus, DORV, PA, VSD, AP-Window
  Hobbs et al                                           2006       USA (C)              ---          ---    ---   ---    ---    ---     ---    127   118   30     48     56     14    0.841     SEQUENCE           Nonsyndromic Septal, Conotruncal, or right- or left-sided ObstructiveHeart Defect
  Zhu et al                                             2006      China (A)              7            22    27     22     57     24    0.328    6    27    23     20     57     25    0.320     PCR-RFLP                                               ASD, PDA
  Zhong et al                                           2006      China (A)             ---          ---    ---   ---    ---    ---     ---    67    33    15     76     34     5     0.558     PCR-RFLP                                       Congenital Heart Disease
  van Beynum et al                                      2006   Netherlands (C)          79            66    20     98    104     18    0.216   72    68    18    131    107     23    0.881     PCR-RFLP           TOF, VSD, Truncus Arteriosus, TGA, AP-Window, TVA, AVSD, PS, AS, HLHS, CoA, PDA,
  Galdieri et al                                        2007     Brazil (M)             30            21     7     18     14     6     0.286   27    15     5     10     15     1     0196      PCR-RFLP                                       Congenital Heart Defects
  Wintner et al                                         2007     Austria (C)            ---          ---    ---   ---    ---    ---     ---    16    12     3     10     17     4     0.708       ARRAY                   TOF,HLHS, TGA, DORV, VSD, AS, CoA, PS, Anomalies of the Aortic Arch
  Liu et al                                             2007      China (A)             30            68    34     46     48     13    0.829   ---   ---   ---   ---    ---    ---     ---      PCR-RFLP                                       Congenital Heart Disease
  van Driel et al                                       2008   Netherlands(C)           99           103    27    119    107     25    0.884   91    117   22    111    104     36    0.166     PCR-RFLP                                TOF, TGA, ASD, VSD, CoA, AS, PS, HLHS,
  Marinho et al                                         2009    Portugal (M)            12            20     6    113    124     14    0.073   ---   ---   ---   ---    ---    ---     ---      PCR-RFLP                                                  TOF
  Obermann-Borst et al                                  2010   Netherlands (C)          64            66     9     92     76     15    1.000   ---   ---   ---   ---    ---    ---     ---      PCR-RFLP                                 TOF, TGA, ASD, VSD, CoA, AS, PS, HLHS
  Hobbs et al                                           2010       USA (C)              ---          ---    ---   ---    ---    ---     ---    285   203   65    191    128     37    0.036     SEQUENCE           Nonsyndromic Septal, Conotruncal, or Right- or Left-sided ObstructiveHeart Defect
  Xu et al                                              2010      China (A)             162          244    96    151    261    115    0.930   ---   ---   ---   ---    ---    ---     ---      PCR-RFLP                Cyanotic Cardiac Disease, ASD, VSD, PDA, Left-sided Obstruction Defects
  García-Fragoso et al                                  2010   Puerto Rico (M)           9            14     4     84    115     21    0.056   10    11     6     84    115     21    0.056     PCR-RFLP                   HLHS, TOF, DORV, TGA, VSD, PS, AS, CoA, ASD, Ebstein\'s Anomaly.
  Kuehl et al                                           2010       USA (C)              12            33    10    134    124     32    0.688   ---   ---   ---   ---    ---    ---     ---        ARRAY                                                   CoA
  Weiner et al                                          2012     Russia (C)             ---          ---    ---   ---    ---    ---     ---    18    21     6    173    149     26    0.514      RT-PCR                               Congenital Anomalies-cardiovascular System
  Zhou et al                                            2012      China (A)             23            60    53     88    126     63    0.183   ---   ---   ---   ---    ---    ---     ---      PCR-RFLP                                                  TOF
  Pishva et al                                          2013    Malaysia (SA)           63            60     0     71     54     0     0.001   ---   ---   ---   ---    ---    ---     ---      PCR-RFLP                                                  VSD
  Mamasoula et al                                       2013        UK(M)              2759          2430   625   4826   4114   1116   0.000   336   396   97    4826   4114   1116   0.000     SEQUENCE                                       Congenital Heart Disease
  Wang et al                                            2013      China(A)              59            76    25     53    100     35    0.377   ---   ---   ---   ---    ---    ---     ---      SEQUENCE                                       Congenital Heart Disease
  Jing et al                                            2013      China (A)             46            42    16     39    114     55    0.164   ---   ---   ---   ---    ---    ---     ---      PCR-RFLP                                       Congenital Heart Disease
  Sahiner et al                                         2013      Turkey(C)             69            53    14     47     39     7     1.000   ---   ---   ---   ---    ---    ---     ---      PCR-RFLP        Obstruction in LV Output, Left-to-right Shunt, Conotruncal Anomalies, Complex Anomalies
  Zidan et al                                           2013     Egypt (AR)             18            21    41     32     21     27    0.000   21    30    29     31     25     24    0.001     PCR-RFLP                             ASD, VSD, PDA, PS, TOF, HLHS, Combined Lesion
  Balderra\' bano-Saucedo et al                         2013     Mexico (M)             ---          ---    ---   ---    ---    ---     ---     7    12    12     24     31     7     0.595     PCR-RFLP                                   Complex Congenital Heart Disease
  Christensen et al [\*\*\*](#t1-fn3){ref-type="fn"}    2013       USA (C)              68            61    28     35     26     8     0.395   67    89    26     27     29     9     0.791     PCR-RFLP                      VSD, TOF, AS, TGA, AVSD, DORV, PS, CoA, Truncus Arteriosus
  Wang et al                                            2013      China (A)             33            92    111    88    126     63    0.183   39    100   96     82    129     66    0.279     PCR-RFLP                                       VSD, ASD, PDA, TOF, DORV
  Huang et al                                           2014      China (A)             63            45    60     84     72     48    0.000   ---   ---   ---   ---    ---    ---     ---    MASS SPECTRUM                                               TOF
  Chao et al                                            2014      China (A)             10            5      2     19     12     3     0.660   ---   ---   ---   ---    ---    ---     ---      PCR-RFLP                                                  PDA

\***: PS**: Pulmonary Stenosis; **HLHS**: Hypoplastic Left Heart Syndrome; **CoA**: Coarctation of the Aorta; **AVS**: Aortic Valve Stenosis; **TGA**: Transposition of Great Arteries; **ASD**: Atrial Septal Defect; **VSD**: Ventricular Septal Defect; **AVSD**: Atrioventricular Septal Defect; **TOF**: Tetralogy of Fallot; **PDA**: Patent Ductus Arteriosus; **DIV**: Double Inlet Ventricle; **PA**: Pulmonary Atresia; **TA**: Tricuspid Atresia; **HLV**: Hypoplastic Left Ventricle; **HRV**: Hypoplastic Right Ventricle; **LVA**: Left Ventricular Aneurysm; **DORV**: Double-outlet Right Ventricle; **AC**: Aortic Coarctation; **AP window**: Atriopulmonary window; **ECD**: Endocardial Cushion Defect; **IAA**: Interrupted Aortic Arch; **LAI**: Left Atrial Isomerism; **RAI**: Right Atrial Isomerism; **TVA**: Tricuspid Valve Atresia; **AS:** Aortic Stenosis.

\*\*: C: Caucasians; A: South Asians; M: Mixed; AR: Arabian.

\*\*\*: The data was respectively provided by author of Dr. **Karen E. Christensen** (see Acknowledgements).

###### The detailed characteristics of all eligible studies for *MTHFR* A1298C polymorphism

                                                                                     *MTHFR* A1298C                                                                                                  
  ---------------------------------------------------- ------ ----------------- -------------------- ----- ----- ----- ----- ----- ------- ----- ----- ----- ------ ------ ------ ------- ---------- -----------------------------------------------------------------------------------------
  Storti et al                                          2003      Italy (C)              45           47    11    101   86    13    0.387   49    46     8    101     86     13    0.387   PCR-RFLP                                VSD,TOF, DORV, PA, d-TGA, AC
  Nurk et al                                            2004     Norway (C)             ---           ---   ---   ---   ---   ---    ---     9    13     3    6607   6342   1525   0.955    RT-PCR                                  Congenital Anomalies Heart
  Galdieri et al                                        2007     Brazil (M)              35           21     1    19    16     3    1.000   26    17     4     15     10     1     1.000   PCR-RFLP                                  Congenital Heart Defects
  van Driel et al                                       2008   Netherlands (C)          112           90    27    97    129   25    0.073   104   102   24    116    104     31    0.319   PCR-RFLP                           TOF, TGA, ASD, VSD, CoA, AS, PS, HLHS,
  Obermann-Borst et al                                  2010   Netherlands (C)           69           57    13    75    90    18    0.256   ---   ---   ---   ---    ---    ---     ---    PCR-RFLP                            TOF, TGA, ASD, VSD, CoA, AS, PS, HLHS
  Xu et al                                              2010      China (A)             316           168   18    326   185   16    0.110   ---   ---   ---   ---    ---    ---     ---    PCR-RFLP          Cyanotic Cardiac Disease, ASD, VSD, PDA, Left-sided Obstruction Defects.
  Weiner et al                                          2012     Russia (C)             ---           ---   ---   ---   ---   ---    ---    33    13     2    168    152     42    0.403    RT-PCR                          Congenital Anomalies-cardiovascular System
  Wang et al                                            2013      China (A)             115           45    10    133   47     8    0.186   ---   ---   ---   ---    ---    ---     ---    SEQUENCE                                  Congenital Heart Disease
  Sahiner et al                                         2013     Turkey (C)              45           68    24    31    54     8    0.029   ---   ---   ---   ---    ---    ---     ---    PCR-RFLP   Obstruction in LV Output, Left-to-right Shunt, Conotruncal Anomalies, Complex Anomalies
  Zidan et al                                           2013     Egypt (AR)              16           27    37    26    24    27    0.001   13    32    25     33     25     22    0.001   PCR-RFLP                        ASD, VSD, PDA, PS, TOF, HLHS, Combined lesion
  Christensen et al [\*\*\*](#t2-fn3){ref-type="fn"}    2013       USA (C)               78           67    12    38    26     5    0.764   98    71    13     36     22     7     0.220   PCR-RFLP                 VSD, TOF, AS, TGA, AVSD, DORV, PS, CoA, Truncus Arteriosus
  Huang et al                                           2014      China (A)             111           56     3    146   56     6    0.800   ---   ---   ---   ---    ---    ---     ---       MS                                                TOF

\***: PS**: Pulmonary Stenosis; **HLHS**: Hypoplastic Left Heart Syndrome; **CoA**: Coarctation of the Aorta; **TGA**: Transposition of Great Arteries; **ASD**: Atrial Septal Defect; **VSD**: Ventricular Septal Defect; **AVSD**: Atrioventricular Septal Defect; **TOF**: Tetralogy of Fallot; **PDA**: Patent Ductus Arteriosus; **PA**: Pulmonary Atresia; **DORV**: Double-outlet Right Ventricle; **AC**: Aortic Coarctation; **AS:** Aortic Stenosis.

\*\*: C: Caucasians; A: South Asians; M: Mixed; AR: Arabian.

\*\*\*: The data was respectively provided by author of Dr. **Karen E. Christensen** (see Acknowledgements).

###### Main results of association between *MTHFR* C677T polymorphism and CHD

                                                Sample size     Test of heterogeneity     Test of association     Test of publication bias                                                                        
  ------------------------ ----------------- --------------- ------------------------- ----------------------- ---------------------------- ------ ----------- ------------------ ---------- ------------- ------ -----------
  **Children Overall**          T vs. C           9,329               15,076                   146.67                     0.000              82.3   **1.248**   **1.093--1.426**   **3.27**    **0.001**    1.13     0.260
                               TT vs. CC                                                       118.35                     0.000              78.9   **1.485**   **1.140--1.935**   **2.93**    **0.003**    0.48     0.628
                               TT vs. CT                                                        53.62                     0.001              53.4   **1.312**   **1.100--1.565**   **3.02**    **0.003**    0.66     0.508
                            Dominant model                                                     102.79                     0.000              74.4   **1.240**   **1.053--1.461**   **2.58**    **0.010**    1.54     0.123
                            Recessive model                                                     89.82                     0.000              72.2   **1.401**   **1.139--1.724**   **3.19**    **0.001**    0.18     0.860
  **Maternal Overall**          T vs. C           3,232               2,7174                    34.32                     0.011              47.6   **1.215**   **1.085--1.361**   **3.38**    **0.001**    0.35     0.726
                               TT vs. CC                                                        32.94                     0.017              45.4   **1.488**   **1.169--1.895**   **3.23**    **0.001**    1.33     0.174
                               TT vs. CT                                                        35.13                     0.009              48.8   **1.315**   **1.042--1.659**   **2.31**    **0.021**    0.98     0.327
                            Dominant model                                                      25.69                     0.107              29.9   **1.258**   **1.144--1.383**   **4.74**   **2.14e-6**   0.70     0.484
                            Recessive model                                                     35.86                     0.007              49.8   **1.408**   **1.128--1.757**   **3.03**    **0.002**    0.91     0.363
  **Caucasian Children**        T vs. C           7,092               12,150                    26.94                     0.003              62.9   **1.163**   **1.008--1.342**   **2.06**    **0.039**    2.18   **0.029**
                               TT vs. CC                                                        18.09                     0.073              44.7     1.273       0.978--1.658       1.79        0.073      0.93     0.350
                               TT vs. CT                                                        9.29                      0.505              0.0      0.986       0.892--1.090       0.28        0.781      0.62     0.533
                            Dominant model                                                      24.13                     0.007              58.6     1.182       0.982--1.422       1.77        0.077      2.34   **0.020**
                            Recessive model                                                     13.12                     0.217              23.8     1.012       0.921--1.113       0.26        0.798      0.47     0.640
  **Caucasian Maternal**        T vs. C           2,431               26,170                    9.22                      0.417              2.4    **1.125**   **1.043--1.214**   **3.04**    **0.002**    0.89     0.371
                               TT vs. CC                                                        7.25                      0.611              0.0      1.157       0.977--1.370       1.69        0.690      0.72     0.474
                               TT vs. CT                                                        6.95                      0.643              0.0      0.945       0.800--1.116       0.67        0.504      0.00     1.00
                            Dominant model                                                      11.03                     0.274              18.4   **1.216**   **1.096--1.348**   **3.69**   **2.24e-4**   0.54     0.592
                            Recessive model                                                     6.58                      0.681              0.0      1.074       0.894--1.227       0.57        0.566      0.54     0.592
  **Asian Children**            T vs. C           1,911                2,222                    74.39                     0.000              86.6   **1.449**   **1.117--1.880**   **2.79**    **0.005**    0.16     0.876
                               TT vs. CC                                                        62.4                      0.000              83.9   **1.960**   **1.203--3.192**   **2.70**    **0.007**    0.16     0.876
                               TT vs. CT                                                        31.57                     0.000              68.3   **1.649**   **1.209--2.248**   **3.16**    **0.002**    0.47     0.640
                            Dominant model                                                      43.94                     0.000              77.2   **1.441**   **1.049--1.978**   **2.26**    **0.024**    0.16     0.876
                            Recessive model                                                     49.87                     0.000              79.9   **1.761**   **1.227--2.526**   **3.07**    **0.002**    0.62     0.533
  **Asian Maternal**            T vs. C            467                  616                     3.96                      0.412              0.0    **1.595**   **1.348--1.886**   **5.45**   **5.04e-8**    --       --
                               TT vs. CC                                                        3.49                      0.479              0.0    **2.548**   **1.788--3.631**   **5.18**   **2.22e-7**    --       --
                               TT vs. CT                                                        1.51                      0.825              0.0    **1.884**   **1.415--2.509**   **4.34**   **1.42e-5**    --       --
                            Dominant model                                                      4.93                      0.295              18.9   **1.605**   **1.215--2.121**   **3.33**    **0.001**     --       --
                            Recessive model                                                     2.05                      0.727              0.0    **2.073**   **1.583--2.716**   **5.29**   **1.22e-7**    --       --

###### Main results of association between *MTHFR* A1298C polymorphism and CHD

                                                Sample size     Test of heterogeneity     Test of association     Test of publication bias                                                                      
  ------------------------ ----------------- --------------- ------------------------- ----------------------- ---------------------------- ------ ----------- ------------------ ---------- ----------- ------ -------
  **Children Overall**          C VS. A           1,834                1,744                    14.21                     0.077              43.7     1.044       0.890--1.225       0.53       0.595     0.31   0.754
                               CC vs. AA                                                        9.05                      0.338              11.6     1.260       0.950--1.671       1.60       0.109     0.10   0.917
                               CC vs. AC                                                        4.56                      0.804              0.00   **1.354**   **1.022--1.793**   **2.11**   **0.034**   1.56   0.118
                            Dominant model                                                      14.34                     0.073              44.2     0.978       0.792--1.206       0.21       0.832     0.36   0.175
                            Recessive model                                                     5.83                      0.666              0.0    **1.322**   **1.015--1.732**   **2.07**   **0.038**   0.52   0.602
  **Maternal Overall**          C VS. A            705                15,458                    16.60                     0.011              63.9     1.041       0.781--1.386       0.27       0.785     0.60   0.548
                               CC vs. AA                                                        11.15                     0.084              46.2     1.085       0.631--1.864       0.29       0.769     0.00   1.000
                               CC vs.AC                                                         2.07                      0.913              0.0      0.841       0.587--1.205       0.94       0.346     0.60   0.548
                            Dominant model                                                      17.61                     0.007              65.9     1.107       0.748--1.639       0.51       0.612     0.60   0.548
                            Recessive model                                                     5.39                      0.495              0.00     0.966       0.690--1.352       0.20       0.839     0.30   0.764
  **Caucasian Children**        C VS. A            765                  796                     6.76                      0.149              40.8     0.989       0.848--1.154       0.14       0.891      --     --
                               CC vs. AA                                                        4.15                      0.386              3.60     1.177       0.819--1.691       0.88       0.378      --     --
                               CC vs. AC                                                        2.22                      0.695              0.00   **1.484**   **1.035--2.128**   **2.15**   **0.032**    --     --
                            Dominant model                                                      7.83                      0.098              48.9     0.916       0.681--1.231       0.58       0.559      --     --
                            Recessive model                                                     2.92                      0.571              0.00     1.332       0.944--1.878       1.63       0.103      --     --
  **Caucasian Maternal**        C VS. A            588                15,352                    9.17                      0.057              56.4     0.920       0.693--1.223       0.57       0.567      --     --
                               CC vs. AA                                                        4.43                      0.364              7.4      0.850       0.565--1.278       0.78       0.434      --     --
                               CC vs. AC                                                        1.25                      0.870              0.00     0.802       0.531--1.212       1.05       0.295      --     --
                            Dominant model                                                      9.22                      0.056              56.6     0.943       0.652--1.363       0.31       0.753      --     --
                            Recessive model                                                     2.77                      0.597              0.00     0.824       0.557--1.217       0.97       0.330      --     --

###### Sensitivity analysis of association between *MTHFR* C677T polymorphism and CHD

                                              Test of heterogeneity     Test of association                                                   
  ---------------------- ----------------- ------------------------- ----------------------- ------ ----------- ------------------ ---------- -------------
  **Children Overall**       TT vs. CT               32.42                    0.020           44.5   **1.303**   **1.064--1.596**   **2.56**    **0.010**
                          Recessive model            61.61                    0.000           70.8   **1.335**   **1.028--1.735**   **2.16**    **0.030**
  **Maternal Overall**        T vs. C                32.48                    0.006           53.8   **1.215**   **1.042--1.425**   **2.48**    **0.013**
                             TT vs. CC               29.99                    0.012           50.0   **1.570**   **1.125--2.192**   **2.65**    **0.008**
                             TT vs. CT               26.09                    0.037           42.5   **1.462**   **1.104--1.937**   **2.65**    **0.008**
                          Dominant model             22.10                    0.105           32.1   **1.198**   **1.035--1.386**   **2.43**    **0.015**
                          Recessive model            29.49                    0.014           49.1   **1.527**   **1.149--2.030**   **2.92**    **0.004**
  **Asian Maternal**          T vs. C                3.96                     0.412           0.0    **1.595**   **1.348--1.886**   **5.45**   **5.04e-8**
                             TT vs. CC               3.49                     0.479           0.0    **2.548**   **1.788--3.631**   **5.18**   **2.22e-7**
                             TT vs. CT               1.51                     0.825           0.0    **1.884**   **1.415--2.509**   **4.34**   **1.42e-5**
                          Dominant model             4.93                     0.295           18.9   **1.605**   **1.215--2.121**   **3.33**    **0.001**
                          Recessive model            2.05                     0.727           0.0    **2.073**   **1.583--2.716**   **5.29**   **1.22e-7**
